Table 1 Baseline characteristics of participants with hybrid SARS-CoV-2 and vaccine induced immunity
Study group | Hybrid immune (n = 24) | Vaccine immune (n = 24) | ||||||
|---|---|---|---|---|---|---|---|---|
Control | CKD | Dialysis | KTR | Control | CKD | Dialysis | KTR | |
Number of participants, n (M:F) | 6 (4:2) | 6 (5:1) | 9 (5:4) | 3 (2:1) | 6 (3:3) | 6 (5:1) | 9 (7:2) | 3 (1:2) |
Age, yr (range) | 58 (22–76) | 70 (62–77) | 63 (39–68) | 61 (24–78) | 57 (39–66) | 64 (21–82) | 69 (48–78) | 47 (37–61) |
BMI, kg/m2 (range)a | 30 (25–33) | 30 (25–33) | 27 (22–38) | 25 (21–28) | 29 (25–37) | 27 (23–32) | 24 (20–33) | 34 (31–35) |
Lymphocytes,109cell/L (range) | 2.1 (1.2–2.3) | 1.5 (0.8–2.4) | 1.2 (0.7–1.9) | 2.4 (1.0–2.4) | 2.6 (1.5–3.7) | 1.6 (1.0–2.1) | 1.4 (0.9–2.4) | 3.7 (2.5–4.9) |
eGFR, mL/min/1.73m2 (range) | 73 (56–125) | 9 (8–21) | — | 58 (31–62) | 81 (61–111) | 15 (11–21) | — | 49 (33–64) |
Dialysis characteristics | ||||||||
Hemodialysis, n (%) | — | — | 7 (78%) | — | — | — | 7 (78) | — |
Peritoneal dialysis, n (%) | — | — | 2 (22%) | — | — | — | 2 (22) | — |
Months on dialysis, n (range) | — | — | 27 (10–481) | — | — | — | 39 (1–379) | — |
Transplant characteristics | ||||||||
Yr post-transplantation (range) | — | — | — | 9 (4–19) | — | — | — | 6 (2–7) |
Living donor, n (%) | — | — | — | 2 (67%) | — | — | — | 3 (100%) |
Immune treatment, n (%) | ||||||||
Azathioprine | — | — | — | 1 (33%) | — | — | — | 0 |
Mycophenolate mofetil | — | — | — | 1 (33%) | — | — | — | 2 (66%) |
Calcineurin inhibitors | — | — | — | 3 (100%) | — | — | — | 3 (100%) |
Serology pre-vaccination | ||||||||
S1 IgG, BAU/mL (range) | 68 (14–743) | 37 (12–313) | 187 (14–768) | 15 (13–80) | 0.2 (0.1–1.2) | 0.4 (0.1–1.2) | 0.9 (0.1–2.7) | 0.6 (0.1–1.7) |
N IgG, AU/mL (range) | 50 (3–242) | 30 (12–108) | 206 (0–875) | 3 (1.0–22) | 2.0 (0.1–2.7) | 2.8 (1.6–22) | 2.9 (1.1–5.4) | 1.8 (0–3.3) |
